{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T22:55:12Z","timestamp":1769381712010,"version":"3.49.0"},"reference-count":30,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2002,3,19]],"date-time":"2002-03-19T00:00:00Z","timestamp":1016496000000},"content-version":"vor","delay-in-days":77,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Anaesthesiol Scand"],"published-print":{"date-parts":[[2002,1]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> There is substantial evidence that cholinomimetic drugs increase pain threshold. However, the profound side effects of these agents have limited their clinical use either as analgesics or as analgesic adjuncts. A delivery system that would assure a slow and sustained drug release may be of value in ameliorating the problem of untoward effects.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> The acetylcholinesterase inhibitor neostigmine was encapsulated into multilamellar lipid vesicles composed of phosphocholine and cholesterol. Three doses of plain or liposomal neostigmine were administered by the intrathecal route to mice (n=8\u201310\/group), and analgesic duration was quantified by tail flick test. The doses were chosen based on preliminary experiments, which showed the maximum tolerated intrathecal doses of plain and liposomal neostigmine formulation were 0.625 \u03bcg and 80 \u03bcg, respectively. Two other doses for each formulation were then derived by 1:1 serial dilutions. Results were compared using survival analysis.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The median antinociceptive duration for plain neostigmine was 0.33, 0.99 and 1.0 h for the 0.115, 0.312 and 0.625 \u03bcg doses, respectively. For the liposomal formulation, the median antinociceptive duration was 1.0, 1.5 and 6.0 h for the 20, 40 and 80 \u03bcg doses, respectively.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> Liposomal neostigmine provides prolonged spinal antinociception, and permits the safe administration of a relatively large dose, because drug is gradually released from the liposomal depot. This technology holds promise for the development of a clinically useful neostigmine formulation to provide spinal analgesia.<\/jats:p>","DOI":"10.1034\/j.1399-6576.2002.460116.x","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T07:47:58Z","timestamp":1027669678000},"page":"90-94","source":"Crossref","is-referenced-by-count":23,"title":["Intrathecal administration of liposomal neostigmine prolongs analgesia in mice"],"prefix":"10.1111","volume":"46","author":[{"given":"G. J.","family":"Grant","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Piskoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bansinath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,3,19]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-1716.1945.tb03087.x"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.3181\/00379727-142-37164"},{"key":"e_1_2_5_4_2","first-page":"75","article-title":"Cholinergic mechanisms in pain and analgesia","author":"Hartvig P","year":"1989","journal-title":"Trends Pharmacol Sci"},{"key":"e_1_2_5_5_2","first-page":"653","article-title":"La geneserine\u2010morphine adjuvant de l'anesthesia generale","volume":"151","author":"Pellandra CL","year":"1933","journal-title":"Lyon Med"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0079-6123(08)60923-1"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-6576.2000.440901.x"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-6576.2000.440904.x"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-199608000-00013"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-199903000-00012"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000539-200005000-00023"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-200002000-00016"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-199911000-00020"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000542-199502000-00003"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000539-199509000-00015"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1213\/00000539-199410000-00015"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-6576.1997.tb04666.x"},{"key":"e_1_2_5_18_2","first-page":"264","article-title":"Prolonged analgesia with liposomal bupivacaine in a mouse model","volume":"19","author":"Grant GJ","year":"1994","journal-title":"Reg Anesth"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4347(00)81242-6"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(80)90515-4"},{"key":"e_1_2_5_21_2","volume-title":"Atlas of the mouse brain and spinal cord","author":"Sidman RL","year":"1971"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(00)01223-4"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0301-0082(93)90045-T"},{"key":"e_1_2_5_24_2","first-page":"470","article-title":"M2, M3 and M4, but not M1, muscarinic receptor subtypes are present in the rat spinal cord","volume":"281","author":"Hoglund AU","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1994.63030815.x"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-8993(99)02456-7"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0703268"},{"key":"e_1_2_5_28_2","first-page":"329","article-title":"Characterization of the anti\u2010nociception produced by intrathecally administered muscarinic agonists in the rats","volume":"266","author":"Iwamoto ET","year":"1993","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1213\/00000539-199710000-00025"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1213\/00000539-198807000-00002"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1213\/00000539-199409000-00015"}],"container-title":["Acta Anaesthesiologica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1399-6576.2002.460116.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1399-6576.2002.460116.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1399-6576.2002.460116.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T06:37:34Z","timestamp":1697524654000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1034\/j.1399-6576.2002.460116.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2002,1]]}},"alternative-id":["10.1034\/j.1399-6576.2002.460116.x"],"URL":"https:\/\/doi.org\/10.1034\/j.1399-6576.2002.460116.x","archive":["Portico"],"relation":{},"ISSN":["0001-5172","1399-6576"],"issn-type":[{"value":"0001-5172","type":"print"},{"value":"1399-6576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,1]]}}}